

University of Zurich Institute of Social and Preventive Medicine



Acute Myocardial Infarction in Switzerland

## AMIS Plus Newsletter Nr. 30 - November 2009

Dear Current & Potential AMIS Plus Participants & Sponsors

## Questionnaire revision

Keeping pace with the ongoing developments in cardiac care demands regular revision of the AMIS Plus Questionnaire. This has been the major undertaking of the AMIS Plus Data Center this year. The revised questionnaire now includes: admission diagnosis, new drugs such as prasugrel, ivabradine, ranolazine, proton pump inhibitors in early drugs as well as anti-rheumatic agents, psychiatric drugs and herbal medicine under regular medication with dronedarone and nicotinic acid being added to discharge medication. Furthermore, new questions on PCI were added in order to document procedures and intervention complications more precisely.

## EPha.ch

Exact collection of drug therapy is extremely important for the AMIS Plus project and we are happy to provide hospitals with the opportunity to collect medication data via EPha.ch (<u>www.epha.ch</u>). This is the perfect tool for collecting data on prescribed drugs, their dosage and possible interactions.



## AMIS Plus Highlights box

The new analysis of 26,159 patients enrolled in the AMIS Plus register reveals the role of pretreatment with  $\beta$ -blocker in patients with acute coronary syndrome (ACS). The results showed that the majority of the ACS patients (71 %) received this therapy. However, considering prescription of  $\beta$ -blocker in ACS patients calls for a tailored approach. Patients who are pretreated should continue to receive  $\beta$ -blocker if they are hemodynamically stable since this medication markedly reduces in-hospital mortality and the rate of major adverse cardiac events. All hemodynamically stable patients without  $\beta$ -blocker pretreatment should receive this therapy soon after presentation for ACS. *Cuculi et al. Cardiology (DOI: 10.1159/000256384)* 

AMIS Plus data were included in a review by Prof. Widimsky entitled "Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries" published online first in the European Heart Journal (*doi:10.1093/eurheartj/ehp492*).

We would like to thank all our participants for their invaluable contribution.

We wish you all a wonderful advent season as you wind down for 2009!

Sincerely yours

For the Steering Committee:

Prof. Paul Erne, MD President

AMIS Plus Data Center Hirschengraben 84 CH-8001 Zurich Tel: +41 (0)44-634 48 30 Fax: +41 (0)44-634 49 86

For the Data Center:

Dragana Radovanovic, MD Head of the Data Center

E-Mail: <u>amis@ifspm.uzh.ch</u> www.amis-plus.ch